Semaglutide — The Next Structural Opportunity for Indian Pharma?

Harshal Dasani02 Mar 2026

With semaglutide’s key patent expected to expire in India around March 2026 and global pricing pressure building, Indian pharma companies may get a structural entry opportunity into the GLP-1 segment. However, complex peptide manufacturing and regulatory barriers mean this is a medium-term execution story, not an immediate earnings trigger.

Continue reading

PSU OFS Wave — Supply Shock or Structural Opportunity?

Harshal Dasani01 Mar 2026

The government’s accelerated OFS program across PSU stocks may create short-term supply pressure, but it does not alter underlying fundamentals. For companies with stable earnings visibility and execution discipline, OFS events represent technical overhangs — not structural deterioration.

Continue reading

India’s Earnings Cycle vs Liquidity Cycle: Which Matters More?

Harshal Dasani24 Feb 2026

Indian equities are shaped by the interplay between liquidity and earnings. Liquidity drives short-term price action, while earnings determine long-term sustainability. With domestic liquidity structurally strong and earnings stabilising, markets appear to be in a multiple-driven phase awaiting broader profit acceleration for a durable bull cycle.

Continue reading
Contact UsWhatsApp